Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $18.5052W HIGH $33.63
Volume
10.96 K
Value Traded
5.84 M
Short % Float
3.75%
Days to Cover
1.5
-3.3%Week
-18.29%1 Month
-10.62%3 Month
-37.46%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
34.64 M
EPS (TTM)
-0.68
P/E Ratio
-
Ent. Value
31.89 M
Total Shares
1.79 M
Float Shares
1.57 M
Insiders
12.57%
Institutions
17.69%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PRPO Catalyst Timeline
Dated clinical, regulatory and corporate events for Precipio, Inc.
Past FDA Catalysts and PDUFA Decisions
How PRPO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Precipio, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PRPO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BCR::ABL1 assay | 2025-12-08 | The joint study with Memorial Sloan Kettering Cancer Center evaluated Precipio’s BCR::ABL1 assay using 895 patient samples, demonstrating superior performance and concordance with two leading platforms, positively impacting patient care and laboratory workflows.Read More | Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Valauri Christina RizopoulosDirector | Grant/Award | 108 5,628 held | $25.24 | 07/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PRPO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PRPO for Q2 2026. | ||||
PRPO Institutional Ownership Trends
PRPO Short Interest
Shares sold short, counted twice a month.
3.75%
Short % of Float
of tradable shares sold short
58.9K
Shares Sold Short
-14.2% vs prior count
1.5 Low
Days to Cover
trading days of normal volume to buy every short share back
39.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PRPO ranks across every disease it competes in
Competitive Position is a premium feature
See how PRPO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPRPO News
-PRPO
Oct 28, 2026▲ +3.6%today
Precipio Announces Q3-2026 Shareholder Update Call
Precipio, Inc. will host its Q3-2026 shareholder update call on November 10, 2026. The call will discuss revenue growth and future plans for 2027. CEO Ilan Danieli will provide insights and a live Q&A session will follow. Investors can submit questions in advance for discussion during the call.
Read more →-PRPO
Aug 14, 2026Precipio Announces Q2-2026 Financial Results
Precipio, Inc. reported strong financial results for Q2-2026, with revenue of $7.0 million, marking a 22% increase year-over-year. The company's adjusted EBITDA reached $0.4 million, reflecting improved operational performance. CEO Ilan Danieli highlighted the company's growth and cash position, emphasizing a healthy recovery without needing financing. A shareholder call is scheduled for August 17, 2026, to discuss these results further.
Read more →-PRPO
Jul 31, 2026Precipio Announces Q2-2026 Shareholder Update Call
Precipio, Inc. will host its Q2-2026 shareholder update call on August 17, 2026. CEO Ilan Danieli expressed optimism about the company's growth and customer acquisition. The call will feature a moderated Q&A session, allowing investors to engage directly with management. A replay will be available post-call on the company's website.
Read more →-PRPO
Jun 12, 2026Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
Precipio, Inc. is urging shareholders to vote their shares before the June 14 deadline to ensure a quorum for the Annual Shareholders Meeting scheduled for June 15, 2026. Currently, only 42% of shares have been voted, and a minimum of 50% is required. Management seeks to avoid the costs associated with adjourning the meeting due to insufficient votes.
Read more →-PRPO
Jun 11, 2026Precipio to Present at the Planet MicroCap Las Vegas
Precipio, Inc. will present at the Planet MicroCap Las Vegas 2026 on June 17, 2026. CEO Ilan Danieli and COO Zaki Sabet will host the presentation, focusing on building shareholder awareness. The event aligns with Precipio's strategy to enhance its shareholder base without seeking additional capital.
Read more →-PRPO
May 14, 2026Precipio Announces Q1 2026 Financial Results
Precipio, Inc. reported its Q1 2026 financial results, showing stable revenue of $6.71 million, slightly up from the previous year. The company anticipates growth in the second half of the year due to an expanding product pipeline. However, challenges included a temporary decline in product revenue and a significant decrease in adjusted EBITDA. The CEO emphasized the importance of assessing non-commercial fluctuations in the business.
Read more →-PRPO
May 13, 2026Management team’s 2025 market-based Options have vested
Precipio, Inc. announced that its management team's 2025 stock options vested after the company's share price rose over 400% from $6 to $30.30. This market-based vesting structure aligns management incentives with shareholder interests, as options only vest with significant price increases. A similar structure is planned for the 2026 stock option grant.
Read more →-PRPO
May 6, 2026▼ -7.4%on this newsshared move
Precipio Announces Q1-2026 Shareholder Update Call
Precipio, Inc. announced it will hold its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM EST. This call will include updates on the company’s core businesses and feature a live moderated Q&A session for shareholders. The introduction of the Q&A session highlights Precipio's dedication to transparency and engagement with its investors. Participants can submit questions in advance and gain insights into the company's performance and strategic direction.
Read more →-PRPO
Mar 13, 2026▼ -6.7%on this news
Precipio Announces Q4 and year-end 2025 Shareholder Update Call
Precipio, Inc. will hold its Q4 and year-end 2025 corporate update call on April 2, 2026. The call aims to provide updates on the company's core businesses and will allow shareholders to submit questions in advance. Precipio focuses on enhancing cancer diagnostics to reduce misdiagnoses and improve patient outcomes.
Read more →-PRPO
Mar 10, 2026Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay
Precipio, Inc. has published a study in collaboration with Memorial Sloan-Kettering Cancer Center, showcasing its Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia (CML). This assay uniquely quantifies all four clinically relevant BCR::ABL1 isoforms, enhancing disease monitoring and treatment decisions. The study analyzed 895 samples, demonstrating significant advantages over existing assays.
Read more →-PRPO
Feb 25, 2026Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
Precipio, Inc. reported preliminary unaudited revenues of $24.0 million for 2025, marking a 30% increase from the previous year. The company has achieved EBITDA and cash-flow positivity, allowing for investments in long-term growth. CEO Ilan Danieli highlighted the positive performance and tripling of shareholder value, with further details expected in an upcoming shareholder call.
Read more →-PRPO
Jan 15, 2026Precipio Takes Major Steps Toward a Clean Balance Sheet
Precipio, Inc. has made significant progress in improving its financial standing by repaying a $1.1 million advance from Change Healthcare and exercising all financial warrants. The company now maintains a debt-free balance sheet, with only a minor loan remaining. CEO Ilan Danieli emphasized the focus on growth and shareholder value.
Read more →-PRPO
Dec 8, 2025Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting
Precipio, Inc. will present findings from a joint study with Memorial Sloan Kettering at the 2025 ASH Meeting. The study, involving 895 patient samples, highlights the superior performance of Precipio's BCR::ABL1 assay and its positive effects on patient care and laboratory workflows. The poster presentation is scheduled for December 8th in Orlando, Florida.
Read more →-PRPO
Dec 4, 2025Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact
Precipio, Inc. reported a limited unauthorized access incident to a data folder in its cloud storage. The breach did not affect operations or patient care, and the company has engaged cybersecurity experts for investigation. Current findings suggest the incident was contained, with no sensitive data compromised. Precipio expects no material impact on its operations or finances.
Read more →-PRPO
Nov 14, 2025Precipio Announces its Q3-2025 Financial Results
Precipio, Inc. reported strong financial results for Q3-2025, with revenues of $6.8 million, reflecting a 30% increase year-over-year. The company achieved positive Adjusted EBITDA of $469,000, a significant improvement from the previous quarter. Cash flow from operations also turned positive, generating $285,000. The Pathology Services Division showed notable growth, indicating a robust customer pipeline.
Read more →-PRPO
Nov 6, 2025Precipio Announces Q3-2025 Shareholder Update Call Call to be held on November 17th, 2025 at 5:00 PM EST
Precipio, Inc. (NASDAQ: PRPO) has announced a Q3-2025 shareholder update call scheduled for November 17, 2025, at 5:00 PM EST. The call will provide updates on the company's core businesses and address questions submitted in advance by investors. Precipio is committed to developing innovative cancer diagnostic solutions that aim to improve accuracy and patient outcomes. A replay of the call will be accessible via the company's Investor page 24 hours later.
Read more →-PRPO
Nov 4, 2025Precipio Announces Q3-2025 Shareholder Update Call
Precipio, Inc. will hold its Q3-2025 corporate update call on November 17, 2025. The call aims to provide insights into the company's current core businesses and will be accessible via phone. Investors can submit questions in advance, and a replay will be available post-call.
Read more →-PRPO
Sep 2, 2025Precipio Terminates Its ATM
Precipio, Inc. has terminated its At-The-Market (ATM) instrument with Alliance Global Partners, signaling a stronger financial position. CEO Ilan Danieli stated that the company no longer needs this tool for capital raises due to improved cash flow and increased cash reserves. This decision reflects Precipio's commitment to responsible capital management and shareholder value.
Read more →-PRPO
Aug 18, 2025Diagnostics Biotech Company NASDAQ: PRPO Founded in 2011 HQ: New Haven, CT DISCLAIM ER T HIS PRESENT AT ION HAS BEE N PREPARE D B Y P RE CIPIO IN C. (T HE “C O MPAN Y”) AND IS GENERA L BA CKGROUND IN FOR MA
Precipio, a diagnostics biotech company, offers a proprietary diagnostics platform that aims to revolutionize blood cancer diagnostics with rapid and cost-effective solutions. The company is projecting significant growth potential as it expands its market footprint into molecular diagnostics valued at over $40 billion. Precipio's innovative testing solutions address critical industry challenges, such as labor shortages and streamline patient care processes. The company maintains a cash flow positive business model and optimizes product delivery through established national distribution partnerships.
Read more →-PRPO
Aug 13, 2025Precipio Announces its Q2-2025 Financial Results
Precipio, Inc. reported a strong Q2-2025 financial performance with revenues reaching $5.7 million, a 27% increase year-over-year. The company anticipates becoming cash flow positive by the end of the year, supported by growth in both its Products and Pathology Services divisions. Adjusted EBITDA showed significant improvement, reflecting effective cost management.
Read more →About Precipio, Inc.
Headquarters4 SCIENCE PARK, NEW HAVEN, CT, 06511
BIOPHARMAWATCH ELITE PLUS
Trade the next PRPO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime